BioPharmSignal logoBioPharmSignal

Biotech News

Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership

Enanta Pharmaceuticals (ENTA)Enanta PharmaceuticalsCompany update

WATERTOWN, Mass. --(BUSINESS WIRE)--Oct. 28, 2026-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, announces today that Jay R.

Related news

ENTAEnanta Pharmaceuticals2026-11-04 12:00 EST

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

ENTAEnanta Pharmaceuticals2026-10-26 11:00 EST

Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)

XFORX4 Pharmaceuticals2026-11-03 21:30 EST

X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026

ZNTLZentalis2026-11-02 22:00 EST

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVIRAtea2026-11-02 21:05 EST

Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026

SPROSpero Therapeutics2026-10-26 13:00 EST

Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline

ZNTLZentalis2026-10-23 14:15 EST

Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026

ANTXAN2 Therapeutics2026-11-02 12:00 EST

AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera

BMYBMYBristol-Myers Squibb Company2026-10-19 10:59 EST

Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026

SCYXSCYNEXIS2026-09-10 12:00 EST

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer

View all latest news

Enanta Pharmaceuticals

Small-Molecule Research Platform Enanta Pharmaceuticals discovers and develops oral small molecules for virology and immunology. Its portfolio applies structure-based drug design to targets that may support convenient, once-daily treatment. EDP-978 KIT Inhibitor EDP-978 is an oral KIT inhibitor in Phase 1 development for chronic...

Recent company news

ENTAEnanta Pharmaceuticals2026-11-04 12:00 EST

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

ENTAEnanta Pharmaceuticals2026-10-28 11:00 EST

Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership

ENTAEnanta Pharmaceuticals2026-10-26 11:00 EST

Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)

ENTAEnanta Pharmaceuticals2026-10-13 11:00 EST

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026

ENTAEnanta Pharmaceuticals2026-09-01 11:00 EST

Enanta Pharmaceuticals to Participate in September Investor Conferences

Stock data

Close
10.08 USD
Market cap
349.81M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States